OSE OSE Immunotherapeutics SA

1.668USD1.521 EUR · EPA+3.75%Mkt Cap: 41.24M USDP/E: —

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi tha…

Key Statistics

Company
Market Cap41.24M USD
Enterprise Value24.99M USD
Revenue (TTM)2.95M USD
Gross Profit2.62M USD
Net Income (TTM)-41.34M USD
Revenue/Share0.13 USD
Last Price1.668 USD
Fiscal Year EndDec 2025
MR QuarterDec 2024
Employees64
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012127173
Valuation
P/E (Trailing)—
P/E (Forward)-1.34
PEG—
EV/EBITDA-0.61
EV/Revenue8.47
P/S13.97
P/B1.23
EPS (TTM)-1.85 USD
EPS (Forward)-1.25 USD
52W Range
1.5652% of range6.471
52W High6.471 USD
52W Low1.565 USD
Profitability
Gross Margin88.70%
Oper. Margin-1392.98%
EBITDA Margin0.00%
Profit Margin-1439.06%
ROE-135.78%
ROA-47.79%
ROIC-90.32%
ROCE-67.77%
Growth
Revenue Growth-0.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-37.33M USD
CapEx (TTM)107.49K USD
FCF Margin-662.85%
FCF Yield-47.44%
Net Debt-14.24M USD
Net Debt/EBITDA0.35
Net Debt/FCF—
Balance Sheet
Debt/Equity1.27
Current Ratio1.28
Quick Ratio1.17
Book Value/Sh1.36 USD
Cash/Share2.76 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.02 USD
Upside (mean)+680.7%
Target Range8.994 USD – 23.03 USD
8.994+680.7% to mean23.03
# Analysts4
Ownership
Shares Out.24.72M
Float17.31M
Insiders25.37%
Institutions2.70%
Technical
SMA 502.338 (-28.7%)
SMA 2003.580 (-53.4%)
Beta1.05
S&P 52W Chg12.00%
Avg Vol (30d)203.77K
Avg Vol (10d)253.14K
Technical Indicators
RSI (14)26.9
MACD-0.1688
MACD Signal-0.1591
MACD Hist.-0.0097
BB Upper2.426 USD
BB Middle1.986 USD
BB Lower1.545 USD
BB Width44.37%
ATR (14)0.1317 USD
Vol Ratio (20d)0.88x

About OSE Immunotherapeutics (EPA: OSE)

›

OSE Immunotherapeutics (EPA: OSE) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 64 employees.

The shares were at 1.521 EUR on 19 November 2026, down 71.6% over 52 weeks. Its 52-week range is 1.427 EUR to 5.900 EUR: the price is 74.2% below the high and 6.6% above the low.

Its market capitalisation is 37.60M EUR.

OSE Immunotherapeutics reports return on equity of -135.8% and revenue down 0.8% year over year.

It holds more cash than debt, a net cash position of 12.98M EUR. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 19 November 2026.